Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy

Am J Trop Med Hyg. 1998 May;58(5):555-8. doi: 10.4269/ajtmh.1998.58.555.


The clinical course of 37 Enterocytozoon bieneusi-infected acquired immunodeficiency syndrome patients with diarrhea was studied. Parasite clearance was seen in 15 patients (40.5%). Clearance of E. bieneusi resulted in a 25-100% reduction in episodes of diarrhea, suggesting that microsporidia are true pathogens. Univariate and multivariate proportional hazards analyses revealed that peripheral blood CD4 cell counts > or = 100/mm3, the use of two or more antiretroviral medications, and use of a protease inhibitor were statistically associated with decreased time to clearance of E. bieneusi. Specific anti-microsporidial therapy (albendazole) was not associated with parasite eradication. Factors related to immunocompetence and human immunodeficiency virus suppression appeared to be important in the clearance of E. bieneusi.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / blood
  • AIDS-Related Opportunistic Infections / parasitology*
  • Acquired Immunodeficiency Syndrome / drug therapy
  • Adult
  • Analysis of Variance
  • Animals
  • Anti-HIV Agents / therapeutic use
  • Humans
  • Immunocompromised Host
  • Intestinal Diseases, Parasitic / etiology
  • Intestinal Diseases, Parasitic / parasitology*
  • Male
  • Microsporida / isolation & purification
  • Microsporidiosis / etiology
  • Microsporidiosis / parasitology*
  • Middle Aged
  • Protease Inhibitors / therapeutic use
  • RNA, Viral / blood*


  • Anti-HIV Agents
  • Protease Inhibitors
  • RNA, Viral